Keyphrases
Transplantation
100%
Tacrolimus
100%
Methotrexate
100%
HLA-matched Donor
100%
Graft-versus-host Disease Prophylaxis
100%
Post-transplantation Cyclophosphamide (PTCy)
100%
Graft-versus-host Disease (GvHD)
21%
High Risk
14%
Older Patients
7%
Disease-free
7%
Separation Analysis
7%
Peripheral Blood
7%
Progression-free Survival
7%
Multivariate Analysis
7%
Bacterial Infection
7%
Viral Infection
7%
Low Risk
7%
Non-relapse Mortality
7%
Myeloablative Conditioning
7%
Relapse-free Survival
7%
Hemorrhagic Cystitis
7%
Single-center Study
7%
Neutrophil Engraftment
7%
Myeloid Malignancies
7%
Hematopoietic Cell Transplantation
7%
Comparative Efficacy
7%
Unrelated Hematopoietic Stem Cell Transplantation
7%
Immunology and Microbiology
Cyclophosphamide
100%
Graft-Versus-Host Disease
100%
Tacrolimus
100%
Methotrexate
100%
Hematopoietic Cell
14%
Cell Transplantation
14%
Engraftment
7%
Myeloid
7%
Viral Disease
7%
Conditioning
7%
Recurrence Free Survival
7%
Acute Graft Versus Host Disease
7%
Neutrophil
7%
Chronic Graft Versus Host Disease
7%
Progression Free Survival
7%